Axelia Oncology
Melbourne, Australia· Est.
Australian biotech developing a systemic TLR2/6 agonist to treat checkpoint‑insensitive solid tumours.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Australian biotech developing a systemic TLR2/6 agonist to treat checkpoint‑insensitive solid tumours.
OncologyImmunology
Technology Platform
Selective systemic TLR2/6 agonism to activate innate immune cells and re‑program the tumour microenvironment without inducing severe cytokine release.
Opportunities
AXA‑042 could address a large unmet need in checkpoint‑resistant solid tumours and serve as a combinatorial partner for existing checkpoint inhibitors, unlocking multi‑partner collaborations.
Risk Factors
Clinical efficacy and safety in humans remain unproven; limited financial runway and competition from other innate‑immune agonists could impede development.
Competitive Landscape
Few companies focus on TLR2/6 agonism; Axelia differentiates by offering a systemic, low‑Cytokine‑Release profile, competing with broader innate‑immune platforms such as BCG, CpG, and STING agonists.